Can the COVID-19 Vaccine Take on COVID Variants?

Can the COVID-19 Vaccine Take on COVID Variants?

Photographs courtesy of www.politico.com

Next month will mark one year since the World Health Organization (WHO) declared the COVID-19 crisis a pandemic. Now the widespread disease presents a slew of additional complications. In recent weeks, a growing presence of mutant COVID-19 variants has surfaced around the globe, including the United States. Two months following the release of the adjunct vaccine, distinctive cases have caused scientists and doctors to voice concerns. Despite global scientific efforts to combat the disease, such variants pose a threat to the effectiveness of the sole form of vaccination. Given the problematic trajectory of countering the disease, further mutations introduce a greater risk than anticipated.

Coined the “South African” and “U.K.” variants, the COVID-19 mutations have already been determined to be more severe the initial mutation. As scientists continue to unearth details regarding the variants, more questions arise. What is currently known, however, is the equally ravaging possibilities of the two variants. Potential findings have led many professionals to believe that the variants may undo progress.

Scientifically referred to as B.1.351, the South African variant was first discovered in the depths of South Africa. Located in Nelson Mandela Bay in October of 2020, the variant was quickly recognized as distinct from the initial strain of COVID-19. As reported by the . Written cases, as well as scientific trials, further describe the variant as an “alarming escape mutant”. Namely, the South African variant is quick to escape some efforts of vaccination, proving to be increasingly resistant to treatment and protection.

Similarly, the U.K. variant is also a cause of concern. Scientifically acknowledged as B.1.1.7, this variant constitutes the greatest danger of all the prominent variants thus far. As scientists recorded its rapid mutation, they noted that it has developed the ability to evade antibodies and generate growing mutations as it hastily diffuses. If such conditions were not already troublesome, the U.K. variant is progressively transmissible by seventy-percent.

The foreseen domino effect suggests a rather strong beginning of a much greater potential issue. If such suggestions prove to be true, the variants could warp the efficacy of the recent two-dose vaccine. Due to the resistant makeup of both variants, the current COVID-19 vaccine may not offer as much protection as currently believed. Both the aforementioned variants, South African and U.K., have the ability to evade antibodies. In terms of vaccination, this indicates that further scientific trials must occur before putting the variants to rest. Without a reliable cure for impending variants, the timeliness of finding one is essential. Scientists are racing to beat the virus and its accompanying variants before additional spread becomes uncontrollable.